Bronchopulmonary disposition of micafungin in healthy adult volunteers

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1218-1220

  Nicasio, Anthony M ^a   Tessier, Pamela R ^a   Nicolau, David P ^a,b   Rnauft, R Fredrick ^c   Russomanno, John ^c   Shore, Eric ^c   L Kuti, Joseph ^a,c  

^a Center for Anti Infective Research and Development   (United States)

^b Division of Infectious Diseases   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN;

ADULT; ARTICLE; BRONCHOSCOPY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BLOOD UREA NITROGEN; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CLINICAL TRIALS, PHASE I AS TOPIC; ECHINOCANDINS; EPITHELIUM; HUMANS; LIPOPEPTIDES; LUNG; MACROPHAGES, ALVEOLAR; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ALVEOLI;

EID: 62949093915     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01386-08     Document Type: Article

References (23)

1. Abe, F., J. Ueyama, N. Kawasumi, M. Nadai, T. Hayashi, M. Kato, M. Ohnishi, H, Saito, N. Takeyama, and T. Hasegawa, 2008. Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotiC., in analbuminemic rats. Antimicrob. Agents Chemother. 52:3454-3456.
2. Antachopoulos, C., J. Meletiadis, T. Sein, E. Roilides, and T. J. Walsh. 2008. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother. 52:321-328.
3. Capitano, B., H. M. Mattoes, E. Shore, A. O'Brien, S. Braman, C. Sutherland, and D. P. Nicolau. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125:965- 973.
4. Chandrasekar, P. H., and J. D. Sobel. 2006. Micafungin: a new echinocandin. Clin. Infect. Dis. 42:1171-1178.
5. Conte, J. E., J. A. Golden, J. Kipps, M. Mclver, and E. Zurlinden. 2004. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob. Agents Chemother. 48:3823-3827.
6. Gotfried, M. H., J.-P. Shaw, B. M. Benton, K. M. Krause, M. R. Goldberg, M. M, Kitt, and S, L, Barriere. 2008. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effects of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob. Agents Chemother. 52:92-97.
7. Groll, A. H., D. Mickiene, V. Petraitis, R. Petraitiene, K. H. Ibrahim, S. C. Piscitelli, I. Bekersky, and T. J. Walsh. 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. 45:3322- 3327.
8. Herbert, M. F., H. E. Smith, T. C. Marbury, S. K. Swan, W. B. Smith, R. W. Townsend, D. Buell, J. Keirns, and I. Bekersky. 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45:1145-1152.
9. Hohl, T. M., and M. Feldmesser. 2007. Aspergillus fumigatus: principles of pathogenesis and host defense. Eukaryot. Cell 6:1953-1963.
10. Hope, W. W., M. J. Kruhlak, C. A. Lyman, R. Petraitiene, V. Petraitis, A. Francesconi, M. Kasai, D. Mickiene, T. Sein, J. Peter, A. M. Kelaher, J. E. Hughes, M. P. Cotton, C. J. Cotten, J. Bacher, S. Tripathi, L. Bermudez, T. K. Maugel, P. M. Zerfas, J. R. Wingard, G. L. Drusano, and T. J. Walsh. 2007. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J. Infect. Dis. 195:455-466.
11. Ibrahim-Granet, O., B. Phillippe, H. Boleti, E. Boisvieux-Ulrich, D. Grenet, M. Stern, and J. P. Latige. 2003. Phagocytosis and intracellular fate of Aspergillus fumigatus conidia in alveolar macrophages. Infect, lmmun. 71: 891-903.
12. Lewis, R. E., N. D. Albert, and D. P. Kontoyiannis. 2008. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 61:1140-1144.
13. Lin, S. J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systemic review of the literature. Clin. Infect. Dis. 32:358-366.
14. Luther, K., M. Rohde, K. Sturm, A. Kotz, J. Heesemann, and F. Ebel. 2008. Characterization of the phagocytic uptake of Aspergillus fumigatus conidia by macrophages. Microbes Infect. 10:175-184.
15. Keirns, J., T. Sawamoto, M. Holum, D. Buell, W. Wisemandle, and A. Alak. 2007. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob. Agents Chemother. 51:787-790.
16. Marr, K. A, M. Boeckh, R. A. Carter, H. W. Kim, and L. Corey. 2004. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39:797-802.
17. Odabasi, Z., V. Paetznick, J. H. Rex, and L. Ostrosky-Zeichner. 2007. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother. 51:4214-4216.
18. Paderu, P., G. Garcia-Effron, S. Balashov, G. Del mas, S. Park, and D. S. Perlin. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
19. Richardson, M. D. 2005. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother. 56(Suppl. 1):5-11.
20. Singh, N., and D. L. Paterson. 2005. Aspergillus infections in transplant recipients. Clin. Microbiol. Rev. 18:44-69.
21. Singh, N., A. P. Limaye, G. Forrest, N. Safdar, P. Munoz, K. Pursell, S. Houston, F. Rosso, J. G. Montoya, P. Patton, R. Del Busto, J. M. Aguado, R. A. Fisher, G. B. Klintmalm, R. Miller, M. M. Wagener, R. E. Lewis, D. P. Kontoyiannis, and S. Husain. 2006. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81:320-326.
22. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
23. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.